



Innovate  
UK

Horizon Europe info is based on DRAFT  
Work Programme and is subject to change

# How to fund innovation and global collaboration

AMR Virtual Mission, 10-12 May 2021

- [UKRI Introduction](#)
- [Horizon Europe Introduction](#)
- [Horizon Europe AMR Funding Opportunities](#)

To keep up to date with the latest Horizon Europe health funding news please sign up for our newsletter [here](#)

Presented by: Jo Frost [ncp-health@innovateuk.ukri.org](mailto:ncp-health@innovateuk.ukri.org)

[Other UK National Contact Points](#) / [National Contact Points for other countries](#)



**HORIZON EUROPE**

THE NEXT EU RESEARCH & INNOVATION  
PROGRAMME (2021 – 2027)

# UK Research and Innovation

We work with the government to **invest over £7 billion a year in research and innovation** by partnering with academia and industry to make the impossible, possible.

Through the UK's nine leading academic and industrial funding councils, we create **knowledge with impact**.

**Innovate UK** drives productivity and economic growth by supporting businesses to develop new ideas



**UK Research  
and Innovation**



UKRI Funding Opportunities: <https://www.ukri.org/opportunity>  
(You can sign up for news and funding alerts on the left of this page)



Innovate  
UK

Horizon Europe info is based on DRAFT  
Work Programme and is subject to change

# Horizon Europe Introduction

To keep up to date with the latest Horizon Europe health funding news please sign up for our newsletter [here](#)

Presented by: Jo Frost [ncp-health@innovateuk.ukri.org](mailto:ncp-health@innovateuk.ukri.org)

[Other UK National Contact Points](#) / [National Contact Points for other countries](#)



**HORIZON EUROPE**

THE NEXT EU RESEARCH & INNOVATION  
PROGRAMME (2021 – 2027)

# What is a National Contact Point (NCP)?

**UK NCP network:** Team of sector specific public servants whose role it is to provide free support to UK participants to Horizon Europe

**International NCP network:** support in Europe and the rest of the World

NCP services vary in each country/sector, but typically include:



**Informing, awareness raising** – on Horizon Europe and other EU programmes



**Assisting, advising and training** – to improve the quality of Horizon Europe proposals



**Signposting and cooperation** – direct to relevant support and work with each other to support consortium development



**Katie Dingley**  
UK Health NCP  
for academia



**Jo Frost**  
UK Health NCP  
for industry  
**LinkedIn**



# European Framework Programmes

- EU research and innovation funding programmes (FPs)
- Began in 1984 and each lasts for 7 years

## Horizon 2020 ran from 2014 until 2020

- The previous Framework Programme (FP) with a total budget of €80 billion.

## Horizon Europe will run 2021 to 2027

- The 9<sup>th</sup> FP and successor to Horizon 2020 with a **€95.5 billion budget**
- Work Programmes due to be published in May 2021 (tbc) although a few calls have already been launched.



The UK has agreed to Associate to Horizon Europe

# UK ‘Association’ means continued UK participation

## EU confirmation of UK participation

### [European Commission Q&A on the UK’s Participation in Horizon Europe](#)

“UK participants will have the **same rights as EU participants...**”

“UK entities are **eligible for funding at the same rates and under the same conditions**”

“They can lead project consortia”

#### **Can UK entities take part in the first calls for proposals of Horizon Europe?**

Yes. UK entities including universities, research centres, scientists, innovative businesses, industry, etc. will have full rights to participate in the first calls for proposals of Horizon Europe as soon as they are published on the [European Commission’s website](#).

This is also true for calls which may be published before the adoption of the Horizon Europe Regulation, such as early COVID-19 calls or those of the European Research Council (ERC) and the European Innovation Council (EIC), apart from the EIC Fund (see below).

In duly justified exceptional cases, restrictions may apply and these will be clearly specified in the calls for proposals.

## The ‘Associated Countries’ concept is not new

- **Horizon 2020 had 16 Associated Countries:** Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Moldova, Montenegro, North Macedonia, Norway, Serbia, Switzerland, Tunisia, Turkey, Ukraine
- **Horizon Europe Associated Countries: exact list is tbc**

# Eligibility

**Eligibility for funding** is usually (unless otherwise stated in the call):

- **Any type of legal entity established in EU Member State (MS) or Associated Country (AC)**
- Legal entities from many Low & Middle Income Countries (LMICs) if country listed in the [Horizon Europe Programme Guide](#)
- International European research organisations
- You can also get funding for organisations in other higher income countries occasionally:
  - If it is specified in your call topic, or
  - If their participation is essential for the project.

**Eligibility for participation** is usually (unless otherwise stated in the call):

- **legal entities from outside EU MS/AC (known as ‘third countries’) can often participate too, although they would normally need to fund their own participation** unless one of the above exceptions applies

Further info: [Work Programme 2021-2022 General Annexes](#) (Section B – Eligibility)

# Horizon Europe structure

Horizon Europe Webinars  
[Intro to Horizon Europe: recording, slides, FAQs](#)  
[Overview of Horizon Europe Clusters - Webinar Series](#)

For info on opportunities for Health researchers across Horizon Europe see the ['related funding' section here](#)



- **€95.5bn** total funding agreed for **2021-2027**
- Budget figures **exclude** UK and other Associate Country contributions so will be higher
- Others likely to associate include Switzerland, Norway & Israel
- Canada, Japan, Australia etc. Interested status (TBC)



Innovate  
UK

Info based on DRAFT Work Programme  
and is subject to change

# Horizon Europe AMR Funding Opportunities - Examples



**HORIZON EUROPE**

THE NEXT EU RESEARCH & INNOVATION  
PROGRAMME (2021 – 2027)

# Horizon Europe


## AMR Opportunities in Pillar II (€53.8 bn 2021-2027)

€53.8bn

### Horizon Europe Webinars

[Intro to Horizon Europe: recording, slides, FAQs](#)  
[Overview of Horizon Europe Clusters - Webinar Series](#)

For info on opportunities for Health researchers across Horizon Europe see the ['related funding' section here](#)



# Horizon Europe – Pillar II – Cluster 1: Health

## Overview (€8.3 billion 2021-2027)

Draft Health Work Programme for 2021-2022 (~€1.75 billion)  
Deadlines tbc and depend on topic: 21 Sept 21, 1 Feb 22, 21 April 22



**Staying healthy in a rapidly changing society**

- Diet and health (obesity)
- Ageing and demographic change
- Mental health
- Digital empowerment in health literacy
- Personalised prevention
- AI to predict disease risk



**Living and working in a health-promoting environment**

- Environmental, occupational and socio-economic risk factors to health, e.g.
- indoor & outdoor air pollution, chemicals, non-ionizing radiation (EMFs)
  - urbanisation, climate and other environmental changes
  - socio-economic inequalities, working environments



**Tackling diseases and reducing disease burden**

- Better diagnostics, personalised treatment
- New and advanced therapies for NCDs
- Scientific evidence, policy, legal frameworks
- Innovative health technologies
- Understanding diseases
- Infectious disease threats



**Ensuring access to innovative, sustainable and high-quality health care**

- Fair access to high quality, sustainable healthcare for all citizens
- Innovative, feasible, implementable, financially sound scalable solutions (for governance, financing, human and physical resources, health service provision and patient empowerment)



**Unlocking the full potential of new tools, technologies and digital solutions for a healthy society**

- Tools, technologies and digital solutions for medical devices and improved health
- considering safety, effectiveness, appropriateness, accessibility,
  - comparative value-added and fiscal sustainability, as well as
  - ethical, legal and regulatory issues



**Maintaining an innovative, sustainable and globally competitive health industry**

- Market access of innovative tech. (medical, pharmaceutical, biotech, digital)
- Novel methodologies and metrics, and support for regulatory authorities
- Safe and clinically validated tools, technologies and services
- Greener pharmaceuticals and technologies

# Horizon Europe – Pillar II

## Example 2021-2022 topics of interest to AMR researchers

Info based on DRAFT Work Programmes,  
so is subject to change

**Pillar II - Cluster 1 'Health'** ([Draft Work Programme](#) as at March 2021, we understand there have only been minor changes since this draft)

- **Vaccines 2.0 - developing the next generation of vaccines**  
(HORIZON-HLTH-2022-DISEASE-06-03-two-stage, page 84 of draft)
- **Development, procurement and responsible management of new antimicrobials**  
(HORIZON-HLTH-2021-IND-07-02, p152 of draft)

### Partnerships



- **A roadmap towards the creation of the European partnership on One Health antimicrobial resistance (OH AMR)**  
(HORIZON-HLTH-2021-DISEASE-04-05, page 76 of draft)
  - Will start ~2024/2025 and will follow on from current JPI AMR
- **Building a European partnership for pandemic preparedness – new, start date tbc**  
(HORIZON-HLTH-2021-DISEASE-04-06:, page 79 of draft)

# Horizon Europe – Pillar II

## Example 2021-2022 topics of interest to AMR researchers

Info based on DRAFT Work Programmes,  
so is subject to change

### Pillar II - Cluster 2 'Culture, Creativity and Inclusive Society' ([Draft Work Programme](#) as at 21 April 2021)

- **Politics and governance in a post-pandemic world**  
(HORIZON-CL2-2021-DEMOCRACY-01-05, p16 of draft)
- **Global governance for a world in transition: Norms, institutions, actors**  
(HORIZON-CL2-2022-DEMOCRACY-01-09, p31 of draft)
- **The role of perceptions, formed by traditions, values and beliefs, in shaping European societies and politics in the 21st century**  
(HORIZON-CL2-2022-HERITAGE-01-03, p54 of draft)

### Pillar II - Cluster 3 'Civil Security for Society' ([Draft Work Programme](#) as at Jan 2021)

- **Improved understanding of risk exposure and its public awareness in areas exposed to multi-hazards**  
(HORIZON-CL3-2021-DRS-01-01, p139 of draft)
- **Enhanced assessment of disaster risks, adaptive capabilities and scenario building based on available historical data and projections**  
(HORIZON-CL3-2021-DRS-01-03, p144 of draft)
- **Developing a prioritisation mechanism for research programming in standardisation related to natural hazards and/or CBRN-E\* sectors**  
(HORIZON-CL3-2021-DRS-01-05, p148 of draft)
- **Improved quality assurance / quality control of data used in decision-making related to risk management of natural hazards, accidents and CBRN\* events**  
(HORIZON-CL3-2022-DRS-01-03, p159 of draft)

\*CBRN (/CBRN-E) = chemical, biological, radiological, nuclear (and explosive) threats

# Horizon Europe – Pillar II

## Example 2021-2022 topics of interest to AMR researchers

Info based on DRAFT Work Programmes,  
so is subject to change

**Pillar II - Cluster 6 'Food, Bioeconomy, Natural Resources, Agriculture and Environment'** ([Draft Work Programme](#) as at April 2021)

### Enabling sustainable farming:

- **Reaching the farm to fork target: R&I scenarios for boosting organic farming and organic aquaculture in Europe**  
(HORIZON-CL6-2021-FARM2FORK-01-01, p143 of draft)
- **Animal welfare 2.0**  
(HORIZON-CL6-2021-FARM2FORK-01-05, p151 of draft)
- **Vaccines and diagnostics for priority animal diseases**  
(HORIZON-CL6-2021-FARM2FORK-01-06, p153 of draft)
- **Enhancing biosecurity in terrestrial livestock production**  
(HORIZON-CL6-2022-FARM2FORK-01-03, p197 of draft)
- **Ecology of infectious animal diseases**  
(HORIZON-CL6-2022-FARM2FORK-02-03-two-stage, p236 of draft)

### Enabling sustainable fisheries and aquaculture:


- **Biosecurity, hygiene, disease prevention and animal welfare in aquaculture**  
(HORIZON-CL6-2022-FARM2FORK-01-06, p203 of draft)

### Targeted International Cooperation (i.e. cooperation with countries outside Europe):

- **One Health approach for Food Nutrition Security and Sustainable Agriculture (FNSSA)** – proposals must involve African organisations  
(HORIZON-CL6-2021-FARM2FORK-01-18, p187 of draft)
- **Agro-ecological approaches in African agriculture systems** – proposals must involve African organisations  
(HORIZON-CL6-2022-FARM2FORK-01-12, p220 of draft)
- **Support for international research on infectious animal diseases**  
(HORIZON-CL6-2022-FARM2FORK-01-15, p228 of draft)

Uniting 28 countries to address AMR

# JPIAMR: A global organisation



International collaborative platform

Aligns national research funding

Coordinates AMR research and funding on a global scale



Supports One Health perspective

Like more info? <https://www.jpiaamr.eu/>  
JPIAMR Newsletter sign-up <https://www.jpiaamr.eu/newsletter-subscription>  
Next call will be on AMR Therapeutics – [Recent workshop/scoping](#)



The European Commission (DG Research) is a full non-voting member

# SRIA: Strategic Research and Innovation Agenda



## Therapeutics



Discovery of new antimicrobials and therapeutic alternatives, and the improvement of current antimicrobials and treatment regimens

## Diagnostics



Development and improvement of diagnostics to improve the use of antimicrobials and alternatives to antimicrobials

## Surveillance



Optimisation of surveillance systems to understand the drivers and burden of antimicrobial resistance in a One Health perspective

## Transmission



Understanding and preventing the transmission of antimicrobial resistance

## Environment



The role of the environment in the persistence, selection and spread of antimicrobial resistance

## Interventions




Investigation and improvement of infection prevention and control measures in One Health settings

# Horizon Europe

## Main 'bottom-up' opportunities

Horizon Europe Webinars  
[Intro to Horizon Europe: recording, slides, FAQs](#)  
[Overview of Horizon Europe Clusters - Webinar Series](#)

For info on opportunities for Health researchers across Horizon Europe see the ['related funding' section here](#)



# Horizon Europe - Pillar I - European Research Council (ERC)

## €16 Billion 2021-2027



- Long term funding of ground-breaking curiosity led, investigator-driven ‘frontier research’
- Funds a Principal Investigator (PI) and their team.
- **Across ALL research fields - completely bottom-up**
- Projects are selected for funding purely based on the excellence (of the PI and of the research project)
- Main types of funding:
  - Starting Grants
  - Consolidator Grants
  - Advanced Grants
  - Synergy Grants

**Like more info?** UK National Contact Point: [erc-uk@ukro.ac.uk](mailto:erc-uk@ukro.ac.uk) / [website](#) / [events](#). [Contact Points in other countries](#)  
[ERC Website](#) including page on [grant schemes](#) / newsletter (sign up at the bottom of the [ERC Website](#))

# Horizon Europe - Pillar I - European Research Council (ERC)

## Summary of main calls 2021 and 2022

| ERC Grant                 | Objectives   | Maximum amount and duration of the grant   | 2021 Call Opening and Closing Dates                     | 2022 Tentative Call Opening and Closing Dates                    |
|---------------------------|--|--|---|--|
| <b>Starting Grant</b>     | Support for excellent Principal Investigators who are starting their own independent research team or programme.<br>Principal Investigator should be between > 2 and ≤ 7 years post PhD  | Up to EUR 1 500 000 for 5 years.<br>Additional funding available   | Call is open<br><b>Deadline: 8 Apr 2021</b>             | Call opens: 23 Sept 2021 tbc<br><b>Deadline: 13 Jan 2022 tbc</b> |
| <b>Consolidator Grant</b> | Support for excellent Principal Investigators at the career stage at which they may still be consolidating their own independent research team or programme.<br>Principal Investigator should be between > 7 and ≤ 12 years post PhD   | Up to EUR 2 000 000 for 5 years.<br>Additional funding available   | Call is Open<br><b>Deadline: 20 Apr 2021</b>            | Call opens: 19 Oct 2021 tbc<br><b>Deadline: 17 Mar 2022 tbc</b>  |
| <b>Advanced Grant</b>     | Support for excellent Principal Investigators at the career stage at which they are already established research leaders with a recognised track record of research achievements.<br>No specific criteria on stage post PhD for Principal Investigator                                 | Up to EUR 2 500 000 for 5 years.<br>Additional funding available   | Call opens: 20 May 2021<br><b>Deadline: 31 Aug 2021</b> | Call opens: 20 Jan 2022 tbc<br><b>Deadline: 28 Apr 2022 tbc</b>  |
| <b>Synergy Grant</b>      | Support for a small group of two to four Principal Investigators to jointly address ambitious research problems that could not be addressed by the individual Principal Investigators and their teams working alone.<br>No specific criteria on stage post PhD Principal Investigators | Up to EUR 10 000 000 for 6 years.<br>Additional funding available<br><i>(information based on 2020 call details)</i> | <b>No call in 2021 Work Programme</b>                   | Call opens: 15 July 2021 tbc<br><b>Deadline: 10 Nov 2021 tbc</b> |
| <b>Proof of Concept</b>   | All Principal Investigators in an ERC frontier research project, that is either ongoing or has ended less within time frame stipulated in work programme are eligible to participate.  | Financial contribution awarded as a lump sum for a defined period.<br>To be set in work programme.                   | <b>Various dates, earliest deadline 14 Oct 2021 tbc</b> |  |

**Like more info?** UK National Contact Point: [erc-uk@ukro.ac.uk](mailto:erc-uk@ukro.ac.uk) / [website](#) / [events](#). [Contact Points in other countries](#)  
[ERC Website](#) including page on [grant schemes](#) / newsletter (sign up at the bottom of the [ERC Website](#))

# Horizon Europe - Pillar I - Marie Skłodowska-Curie Actions (MSCA)

€6.6 Billion 2021-2027



Are you looking for excellent researchers and innovators?

Do you want to develop new and strengthen existing collaborations?

- Marie Skłodowska-Curie Actions (MSCA) are **completely bottom up** and **open to all areas** of research at all stages - from **basic frontier research to near market uptake**
- Provide funding for all researcher career stages as well as managerial, administrative or technical staff

**MSCA aim to:**

- **Enhance the career development and training** of researchers and innovators
- Promote **international, inter-sectoral and interdisciplinary collaboration and mobility**
- **Bridge academic and non-academic sectors in and outside of Europe**
- **Promote sharing of knowledge and ideas** from research to market (and vice versa)
- Foster a shared culture of R&I that welcomes and **rewards creativity and entrepreneurship**

# Horizon Europe - Pillar I - Marie Skłodowska-Curie Actions (MSCA)


€6.6 Billion 2021-2027

Open to all areas of research and innovation



## MSCA Doctoral Networks

- Provides full funding for an international consortium to train a group of PhD students
- Provides recruited researchers with training through research
- **Mobility is key** – intersectoral, interdisciplinary and international!



## MSCA Staff Exchange Scheme

- Funds short-term exchanges of personnel between academic, industrial and commercial organisations throughout the world
- Funds consortium based research and innovation projects
- Project implemented through the secondment of staff for a period between 1 and 12 months



## MSCA Post Doctoral Fellowships

- Provides full funding for an individual postdoctoral researcher
- **Mobility is key** – intersectoral, interdisciplinary and international!
- **Training through research and innovation**
- Opportunities for European or internationally hosted fellowships with opportunities for secondments

**NEW:** Extra 6 months funding for fellow to spend time in non-academic setting



## MSCA COFUND Doctoral and Fellowship Programme

- Collaborative funding through a mono beneficiary scheme
- Training through research and innovation
- Mobility is key – intersectoral, interdisciplinary and international!
- EC provides a contribution to the funding for a cohort of PhD students or Post-Docs

# Horizon Europe - Pillar I - Marie Skłodowska-Curie Actions (MSCA) €6.6 Billion 2021-2027


| Year | Action                                | Estimated opening*       | Estimated deadline* |
|------|---------------------------------------|--------------------------|---------------------|
| 2021 | Doctoral Networks                     | 18 May 2021              | 16 November 2021    |
|      | Postdoctoral Fellowships              | 18 May 2021              | 15 September 2021   |
|      | Staff Exchanges                       | 7 October 2021           | 9 March 2022        |
|      | COFUND                                | 12 October 2021          | 10 February 2022    |
|      | MSCA and Citizens (covers 2 editions) | 17 June 2021             | 7 October 2021      |
| 2022 | Doctoral Networks                     | 3 May 2022               | 15 November 2022    |
|      | Postdoctoral Fellowships              | 13 April 2022            | 14 September 2022   |
|      | Staff Exchanges                       | 6 October 2022           | 8 March 2023        |
|      | COFUND                                | 11 October 2022          | 9 February 2023     |
|      | MSCA and Citizens                     | No call foreseen in 2022 |                     |

*\*Dates to be confirmed with the adoption of the Work Programme*

# Horizon Europe – Pillar III – European Innovation Council (EIC)

(European Innovation Council – brings together H2020 Future and Emerging Technologies with SME Instrument)

*‘Integrated, agile support across the full R&D spectrum from early stage research to scale-up’*



## Pathfinder Open (bottom up, no pre-defined topics)

Advanced research to develop the scientific basis to underpin breakthrough technologies, oriented around ‘gatekeepers’:

- Radical technology vision
- Breakthrough target
- Novel interdisciplinary

Collaborative, ~€3M (no cap), 100%

## Pathfinder Challenges (top-down in specific technology areas)

**2021 topics include**

- Aware inside
- Tools for brain activity
- Cell and gene therapy
- Green hydrogen
- Living materials

## Transition Open (bottom up, no pre-defined topics)

Validate technologies and develop business plans for specific applications, **builds on EIC Pathfinder projects and ERC Proof of Concept projects.**

Single entity or collaborative, ~€2.5M (no cap), 100%

## Transition Challenges (top-down in specific tech. areas) 2021 topics

- Medical technology and devices: from lab to patient
- Energy harvesting

Challenges can be single/mono beneficiary, €4M, 100%

## Accelerator Open (bottom-up, no predefined topics)

## Accelerator Challenges 2021 topics:

- Strategic Health and Digital Technologies
- Green Deal Innovations for Economic recovery

Like more info? Pathfinder UK contact: [dora.meredith@innovateuk.ukri.org](mailto:dora.meredith@innovateuk.ukri.org)

Transition/Accelerator UK contact: [genevra.kirby@innovateuk.ukri.org](mailto:genevra.kirby@innovateuk.ukri.org)

[National Contact Points in other countries](#)

[EIC Applicants' Day recording & presentations](#) / [EIC website](#) / [2021 Work Programme](#)


# Horizon Europe – Pillar III – European Innovation Council (EIC)

**Table 1. Summary of main calls in 2021<sup>8</sup>**

|                        | Who can apply   | What for   | Open calls (Section II)   |                                 | Challenge driven calls (Section III)   |   |                                |
|------------------------|---|--|---|---------------------------------|--|---|--------------------------------|
|                        |   |  | Call deadline(s)  | Indicative Budget (EUR million) | Challenges   | Call deadline(s)  | Indicative Budget(EUR million) |
| <b>EIC Pathfinder</b>  | Consortia of at least three different independent legal entities (e.g. research organisations, universities, SMEs, industry) established in at least 3 different eligible countries. Single applicants or small consortia (two partners) may be able to apply for Pathfinder Challenges according to the call specifications. | Grants of up to EUR 3 million (open) or EUR 4 million (challenge driven) (or more if properly justified) to achieve the proof of principle and validate the scientific basis of breakthrough technology (TRL 1-4)  | 19 May 2021   | 168.00                          | <ol style="list-style-type: none"> <li>1. Awareness inside</li> <li>2. Tools to measure &amp; stimulate activity in brain tissue</li> <li>3. Emerging Technologies in Cell &amp; Gene Therapy</li> <li>4. Novel routes to green hydrogen production</li> <li>5. Engineered living materials</li> </ol> | 27 October 2021   | 132.00                         |
| <b>EIC Transition</b>  | Single applicants (SMEs, spin-offs, start-ups, research organisations, universities) or small consortia (two to 5 partners). Applications must build on results from eligible Pathfinder, FET or ERC Proof of Concept projects  | Grants of up to EUR 2.5 million (or more if properly justified) to validate and demonstrate technology in application-relevant environment (TRL 4 to 5/6) and develop market readiness   | 22 September 2021   | 59.60                           | <ol style="list-style-type: none"> <li>1. Medical devices</li> <li>2. Energy harvesting and storage technologies</li> </ol>  | 22 September 2021   | 40.50                          |
| <b>EIC Accelerator</b> | Single Start-ups and SMEs (including spin-outs), individuals (intending to launch a start-up/SME) and in exceptional cases small mid-caps (fewer than 500 employees)  | Blended finance: up to EUR 2.5 million grant component for technology development and validation (TRL 5/6 to 8); EUR 0.5 - 15 million investment component for scaling up and other activities. Grant only/grant first under certain conditions. Investment component only for small mid-caps or as follow up to grant only (i.e. for SMEs, including start-ups) | Any time (short applications) Full applications by 9 June 2021 and 6 October 2021 | 592.50                          | <ol style="list-style-type: none"> <li>1. Strategic Health and Digital Technologies</li> <li>2. Green Deal innovations for the economic recovery</li> </ol>  | Any time (short applications) Full applications by 9 June 2021 and 6 October 2021 | 495.10                         |

# Horizon Europe – Pillar III

## European Innovation Ecosystems (EIE)



Eureka Countries

### Likely to fund the successor to the Eurostars programme

- Eurostars is a joint programme between Eureka and the European Commission
  - It is co-funded from the national budgets of participating Eureka member countries
- **Funds transnational, market-oriented, collaborative R&I projects**
  - **Projects must be initiated and driven by Research and Development performing SMEs**
  - **Normally bi-annual calls which are open in scope** (next call opens July and closes Oct 2021 tbc)
- There are over 45 Eureka member countries including the UK
  - 36 of these countries take part in the Eurostars programme including non-European countries such as Canada, South Korea and South Africa
- Projects can be both bilateral and multilateral
  - For example a UK SME collaborating with an SME/other organisations from any other participating Eureka member country (does not have to be an SME from an EU Member State)
- The rules about which countries and which types of organisations are funded are explained in the call documents.
- Taking part in a Eurostars project can help growth, innovation, open new global markets and lead to greater business success
- ~1/3 of projects centre around Health and Life Sciences, 1/3 of projects centre around the Data and ICT economy, and a 1/3 are mix of several other sectors

### Other Eureka funding schemes

- **Globalstars** – Funds projects involving Eureka and non-Eureka countries - each call specifies the countries involved
- **Network Projects**
- **Eureka Clusters**

# Horizon Europe - Widening participation and strengthening the European Research Area (ERA)

Includes:

- [COST](#) (European Co-operation in Science and Technology):
  - **COST Open Call** (regular deadlines, next deadline 29 Oct 2021 12pm CET)
    - **Open to all areas of research and innovation** (bottom-up)
    - **Funding to set up interdisciplinary research and innovation networks in Europe and beyond**
      - Funding for organising meetings, training schools, short term scientific missions or other networking
      - Networks run for 4 years and help to build capacity.
    - Funds global networking of nationally-funded research.
  - You can also [join](#) the [existing COST actions](#)
    - e.g. European Network for Optimisation of Veterinary Antimicrobial Treatment – [website](#) / [newsletter](#)
- **ERA Talent Platform** for career development of researchers, with particular focus on talented researchers and opening new career trajectories for them in academia, industry and business.
  - The new platform will build on the existing [EURAXESS](#) platform which **supports researcher mobility and career development**
  - Includes info on jobs, funding, career development, [partnering](#), practical info on living and working in Europe and beyond including the UK, EURAXESS national portals include the [UK](#) Portal run by the British Council)



Innovate  
UK



Medical  
Research  
Council

Horizon Europe info is based on DRAFT  
Work Programme and is subject to change

Thank you

Extra slides for reference only

- General (UK Association. Useful definitions)
- European Institute of Innovation and Technology (EIT)
- JPI AMR
- Other 'Partnerships' in Horizon Europe Health
- Eureka



To keep up to date with the latest Horizon Europe health funding news  
please sign up for our newsletter [here](#)

Presented by: Jo Frost [ncp-health@innovateuk.ukri.org](mailto:ncp-health@innovateuk.ukri.org)

[Other UK National Contact Points](#) / [National Contact Points for other countries](#)

HORIZON EUROPE

THE NEXT EU RESEARCH & INNOVATION  
PROGRAMME (2021 – 2027)



## UK 'Association' means continued UK participation

- The UK has agreed to associate to Horizon Europe
- UK entities will have **equivalent participation rights** to those from Member States\*
  - **Only two very rare** exceptions:
    - The equity fund part of the EIC Accelerator, as the UK decided not to take part in this (the UK can still take part in the rest of the EIC including the grants part of the EIC Accelerator)
    - Work Programme level exclusions only in exceptional and justifiable cases (e.g. some Defence & Security)
- UK entities **can lead projects as coordinator**
- **UK experts** can continue to take part in peer review (register as an expert [here](#))
- The UK can also still participate in the **governance** of Horizon Europe (e.g. Programme Committees)
- **The 'Associated Countries' concept is not new**
  - Horizon 2020 had 16 Associated Countries including Israel, Switzerland and Norway

# Some definitions

- **Work Programme** – combined calls for proposals for the whole thing (excluding Institutionalised partnerships who do their own)
- **Cluster** – a major problem space. There are six in total. Cluster 1 is health
- **Destination** – a way of breaking down the Cluster to manageable chunks with a common theme, e.g., decarbonisation of transport
- **Topic** – a specific call for proposals with its own scope, budget, etc. Often (but not always) more than one project will be funded.
- **The Portal** – the [EU Funding & Tenders Portal](#) where all information needed to participate can be found
- **PIC** – Participant Identification Code – a unique identifier for each participating legal entity
- **LEAR** – Legal Entity Appointed Representative – a single person at the top for each organisation, often Chief Finance Officer or similar (buck stops with them)
- **Coordinator** – The lead participant for a proposal and project who brings the team together, submits the proposal and manages delivery of the project



Innovate  
UK



Medical  
Research  
Council

Info based on DRAFT Work Programme  
and is subject to change

# Extra slides for reference only - European Institute of Innovation and Technology (EIT)



**HORIZON EUROPE**

THE NEXT EU RESEARCH & INNOVATION  
PROGRAMME (2021 – 2027)

# Horizon Europe – Pillar III – European Institute of Innovation and Technology Knowledge and Innovation Communities (EIC KICS)

(€3 billion 2021-2027)

- The EIT brings together business, education and research bodies to create an environment conducive to innovation and entrepreneurship in Europe
- It funds 8 long-term partnerships, KICs, each with a focus on a different societal challenges:



New KICs for Culture and Creative Industries and Water, Marine and Maritime Sectors and Ecosystems are anticipated in 2022/3 and 2026 respectively

- Calls for projects starting this year have already closed but calls for projects starting in 2022 are open or due to be open later this year and you can apply to become a partner at any time
- Calls for proposals are primarily open for existing partners. However, non-partners are able to participate



Innovate  
UK



Medical  
Research  
Council

Info based on DRAFT Work Programme  
and is subject to change

# Extra slides for reference only - JPI AMR



**HORIZON EUROPE**

THE NEXT EU RESEARCH & INNOVATION  
PROGRAMME (2021 – 2027)

# Overview of JPIAMR supported research



**>100 M€**

Total Investment



**117**

|          |    |
|----------|----|
| Projects | 79 |
| Networks | 38 |




**1285**

> From 71 different countries

Researchers

Researcher Location



© OpenStreetMap contributors

-  **32 LMICs involved**
-  **80 researchers from LMICs**
-  **25 research project and networks with LMIC elements in their research scope**


One Health perspective

**38%**


Projects with One Health aspect




# JPIAMR: A global One Health AMR Research Funder



- Supported 79 research projects and 38 research networks
- Invested >100 M€



33% of investment in research projects is in Transmission followed by Therapeutics (29%)



34% of investment in research networks is in Surveillance followed by Interventions (22%)

# Dashboard on JPIAMR supported research projects and networks

## JPIAMR Supported Research Projects and Networks Dashboard

Click and select multiple criteria for interactive analyses throughout the dataset. Press **F5** to clear selections.

Total sum awarded (M€)  
**80.16**

Number of project(s)  
**99**

Number of researcher(s)  
**1,180**



Search by Country


Search by Funding scheme

Research Network

Research Project


Search for Funder

### Project Funding per priority area (M€)




Select the specific research area to see detailed information.

### Investment by funding organisations (M€)




Select the name of the funder to see detailed information. Scroll the bar across the graph to see information on other funders.

### Projects per priority area



Select the specific research area to see detailed information.

### Researchers in different types of research organisations



Select the specific type of research organisation to see detailed information.

### Research projects details

Search by project acronym

Search by role of the researcher

| Title of the project  | Name of the researcher | Country         | Organisation                         | Project information   | Start date of the project | End date of the project | ORCID id  |
|---|------------------------|-----------------|--------------------------------------|---|---------------------------|-------------------------|---|
| A digital antimicrobial stewardship smartphone application to combat AMR: the | Annelies Verbon        | Czech Republic  | Charles University                   | <a href="https://www.jpiamr.eu/project/ab-assistant/">https://www.jpiamr.eu/project/ab-assistant/</a> | 9/1/2017                  | 8/31/2020               | <a href="https://orcid.org/0000">https://orcid.org/0000</a> |
| A digital antimicrobial stewardship smartphone application to combat AMR: the | Annelies Verbon        | Czech Republic  | Charles University                   | <a href="https://www.jpiamr.eu/project/ab-assistant/">https://www.jpiamr.eu/project/ab-assistant/</a> | 2/1/2018                  | 1/31/2021               | <a href="https://orcid.org/0000">https://orcid.org/0000</a> |
| A digital antimicrobial stewardship smartphone application to combat AMR: the | Annelies Verbon        | Czech Republic  | Charles University                   | <a href="https://www.jpiamr.eu/project/ab-assistant/">https://www.jpiamr.eu/project/ab-assistant/</a> | 2/1/2018                  | 1/2/2022                | <a href="https://orcid.org/0000">https://orcid.org/0000</a> |
| A digital antimicrobial stewardship smartphone application to combat AMR: the | Annelies Verbon        | The Netherlands | Erasmus MC University Medical Center | <a href="https://www.jpiamr.eu/project/ab-assistant/">https://www.jpiamr.eu/project/ab-assistant/</a> | 9/1/2017                  | 8/31/2020               | <a href="https://orcid.org/0000">https://orcid.org/0000</a> |
| A digital antimicrobial stewardship smartphone application to combat AMR: the | Annelies Verbon        | The Netherlands | Erasmus MC University Medical Center | <a href="https://www.jpiamr.eu/project/ab-assistant/">https://www.jpiamr.eu/project/ab-assistant/</a> | 2/1/2018                  | 1/31/2021               | <a href="https://orcid.org/0000">https://orcid.org/0000</a> |
| A digital antimicrobial stewardship smartphone application to combat AMR: the | Annelies Verbon        | The Netherlands | Erasmus MC University Medical Center | <a href="https://www.jpiamr.eu/project/ab-assistant/">https://www.jpiamr.eu/project/ab-assistant/</a> | 2/1/2018                  | 1/2/2022                | <a href="https://orcid.org/0000">https://orcid.org/0000</a> |

Click and select multiple criteria for interactive analyses throughout the dataset. Press **F5** to clear selections.





Innovate  
UK



Medical  
Research  
Council

Info based on DRAFT Work Programme  
and is subject to change

# Extra slides for reference only - Other 'Partnerships' in Horizon Europe Health



**HORIZON EUROPE**

THE NEXT EU RESEARCH & INNOVATION  
PROGRAMME (2021 – 2027)

# Horizon Europe – Health - Partnerships

Partnerships bring together the European Commission and private and/or public partners together to tackle pressing challenges

- 9 European ‘Partnerships’ in Health are proposed for the first half of Horizon Europe (with further partnerships in later years)

## Institutionalised Partnerships

- These partnerships (once established by the European Commission) will hold calls for proposals. First calls are expected ~Q4 of 2021.
  - **Innovative Health Initiative** - successor to the Innovative Medicines Initiative - but also broadened to include prevention, diagnostics, treatment and disease management incl. Pharma, Biotech, MedTech, Vaccines, Radiological, Electromedical and the Healthcare IT Industry. Subscribe to the IMI newsletter [here](#).



Data Source: [IMI Website](#), 13 May 2021

# Horizon Europe – Health - Partnerships

Partnerships bring together the European Commission and private and/or public partners together to tackle pressing challenges

- 9 [European ‘Partnerships’](#) in Health are [proposed for the first half of Horizon Europe](#) (with further partnerships in later years)

## Instiutionalised Partnerships

- These partnerships (once established by the European Commission) will hold calls for proposals. First calls are expected ~Q4 of 2021.
  - **Innovative Health Initiative** - successor to the [Innovative Medicines Initiative](#) - but also broadened to include prevention, diagnostics, treatment and disease management incl. Pharma, Biotech, MedTech, Vaccines, Radiological, Electromedical and the Healthcare IT Industry. Subscribe to the IMI newsletter [here](#).
  - **EU-Africa Global Health** ([EDCTP3](#)) - to reduce the burden of infectious diseases & strengthen research capacities. [Newsletter..](#)
- UK based orgs. are eligible for funding from calls by the Innovative Health Initiative (IMI3) and Global Health Partnership (EDCTP3)

## Co-funded Partnerships

- Jointly funded calls where the EU partners with research funders and other public authorities in some MS/AC/other countries.



- Countries involved depend on each partnership (and call) so UK eligibility for calls run by each Health Co-funded partnership is tbc.
  - **Chemicals Risk Assessment**
  - **European Partnership – European Research Area (ERA) for Health Research**
  - **Health and Care Systems Transformation**
  - **Personalised Medicine**
  - **One Health/AMR Antimicrobial Resistance (AMR)**
  - **Rare Diseases**
  - **Pandemic Preparedness (new)**

| European Partnership on  | Info                                      | Related 2021/2022 Work Programme Topics  | Work Programme Year | Partnership Start Year |
|--|---|--|---------------------|------------------------|
| <b>Assessment of Risk of Chemicals (PARC)</b><br>(replaces EJP Human Biomonitoring)                  | <a href="#">Draft proposal</a>            | <b>Partnership establishment:</b><br>HORIZON-HLTH-2021-ENVHLTH-03-01: European Partnership for the Assessment of Risks from Chemicals (PARC)<br>Cofund with EC contribution of €200 million  | 2021                | 2022                   |
| <b>Transforming Health &amp; Care Systems</b><br>(replaces AAL, JPI Ageing...)                       | <a href="#">Draft proposal</a>            | <b>Partnership establishment:</b><br>HORIZON-HLTH-2022-CARE-10-01: European Partnership on Transforming Health and Care Systems<br>Cofund with EC contribution of €100 million   | 2022                | 2023                   |
| <b>Fostering a European Research Area (ERA) for Health</b> (replaces ERA-CVD, EuroNanoMed, JPI HDHL) | <a href="#">Draft proposal (May 2019)</a> | <b>Partnership establishment:</b><br>HORIZON-HLTH-2022-DISEASE-03-01: European Partnership Fostering an ERA for Health research – Placeholder<br>Cofund with EC contribution of €30 million for initial stage?<br>This partnership <i>might</i> deploy large scale investigator initiated clinical studies (tbc) | 2022?               | ?                      |
| <b>Personalised Medicine</b><br>(replaces ICPeMed and the linked ERA-PerMed)                         | <a href="#">Draft outline (May 2019)</a>  | <b>Preparatory work:</b><br>HORIZON-HLTH-2021-STAYHLTH-01-04: A roadmap for personalised prevention  | 2023                | 2023                   |
| <b>Rare Diseases</b><br>(replaces JPI Rare Diseases, ERA-NET Rare Diseases)                          | <a href="#">Draft outline (May 2019)</a>  | ?  | 2023                | 2024                   |
| <b>One Health AMR</b><br>(replaces JPI AMR, ERA-NET Rare Diseases)                                   | <a href="#">Draft outline (May 2019)</a>  | <b>Preparatory work:</b><br>HORIZON-HLTH-2021-DISEASE-04-05: A roadmap towards the creation of the European One Health antimicrobial resistance partnership (OH AMR)   | 2023/24             | 2024/25                |
| <b>Pandemic Preparedness</b><br>(new initiative)   |   | <b>Preparatory work:</b><br>HORIZON-HLTH-2021-DISEASE-04-06: Building a European Research and Innovation Partnership for Pandemic Preparedness   | ?                   | ?                      |



Info based on DRAFT Work Programme, so is subject to change




Innovate  
UK



Medical  
Research  
Council

Info based on DRAFT Work Programme  
and is subject to change

# Extra slides for reference only - Eureka



**HORIZON EUROPE**

THE NEXT EU RESEARCH & INNOVATION  
PROGRAMME (2021 – 2027)



Innovate  
UK

# EUREKA

The world's largest network for international co-operation in R&D and Innovation, present in over 40 countries




# What is EUREKA?

- Established in 1985 to support cross border business-led R&D and Innovation
- Trusted framework facilitating bilateral and multilateral collaboration
- Involves 44 countries with the potential to expand and to work with other countries
- Supports globalisation of businesses with innovative ideas



# The Global Reach of the EUREKA Network



Innovate  
UK



More than €38 billion  
invested

1985

11600+

SMEs

3800

+

Universities

4000

+

Research  
Centres


7300

+

Large  
Companies

● Total budget

● Total number of  
projects



TODAY

More than 6400 projects  
launched




# Impact

Strengthened commercial position of participating companies



69%

Enter new markets



68%

Improved market shares



67%

Increased exports



69%

Increase in research staff



64%


Increase in general staff




62%

Overall improvement in competitive position


# EUREKA Characteristics



Market-oriented  
nature



Innovative  
product, process  
or service



Bottom-up  
approach




Global  
cooperation


# Motives for participation




International  
co-operations  
70%+




New business  
opportunities  
60%+



High degree  
of flexibility



Freedom to  
create consortia



Strong bottom-up  
approach

# EUREKA Instruments



## EUREKA NETWORK PROJECTS

enable bottom-up bilateral and multilateral projects between any country in the EUREKA Network in any area.



## EUREKA EUROSTARS

enables collaborative projects (2 cut off dates per year) in any area with projects led by Small and Medium Enterprises (SMEs).



## EUREKA CLUSTERS

are industry driven public-private partnerships which build communities and convene projects between SMEs and large industry in specific technology and market areas.



## EUREKA GLOBALSTARS

calls enable collaborative projects between any country in the EUREKA Network and countries outside the EUREKA Network in any area.



Innovate  
UK

**EUREKA**   
innovation across borders

# EUREKA Network Projects



Innovative product, process or service with a civilian purpose




Participants from at least two EUREKA countries



No thematic restrictions but projects need to reflect market demand



National evaluation procedures & funding



# A typical Network project is...



**3** participants



**2-3**  
countries



average duration  
**28** months



average project cost  
**€1.3** million

# Eurostars is...



Joint programme  
between EUREKA  
and EU



Dedicated  
to R&D-  
performing SMEs



Market-oriented




Bottom-up



International  
cooperation


# Eurostars II Countries



36 countries

- |  |  |   |
|--|--|---|
|  Austria          |  Germany      |  The Netherlands   |
|  Bulgaria         |  Greece       |  Norway            |
|  Belgium          |  Hungary      |  Poland            |
|  Canada           |  Iceland      |  Portugal          |
|  Croatia         |  Ireland     |  Romania          |
|  Cyprus         |  Israel     |  Slovak Republic |
|  Czech Republic |  Italy      |  Slovenia        |
|  Denmark        |  Latvia     |  South Africa    |
|  Estonia        |  Lithuania  |  South Korea     |
|  Finland        |  Luxembourg |  Spain           |
|  France         |  Malta      |  Switzerland     |
|  |  |  Turkey          |
|  |  |  United Kingdom  |

# SMEs in the driving seat



# A typical Eurostars project is...



**3-4**  
participants



**2-3**  
countries



average duration  
**30** months



average project cost  
**€1.4** million

# UK Eligibility

- In the UK, only SMEs are eligible for funding.
- The project must be led by a research-performing SME, one that:
  - invests 10% or more of its turnover into research, or
  - has 10% of its full-time equivalent staff working on research activities, or
  - has 5 or more full-time staff working on research activities, if the SME has 100 or fewer employees, or
  - has 10 or more full-time staff working on research activities, if the SME has more than 100 employees
- UK subcontracting is capped at 20% of the UK partner eligible costs.
- You must follow:
  - the [Eurostars eligibility criteria](#) and
  - these Innovate UK criteria at the competition application deadline and throughout your project



Aim higher

# Factors for success

- Be technologically ambitious while remaining realistic - define a methodical approach in line with partnership, budget and time limit set for the completion of the project and the marketing of its results.
- Point out the innovative nature of the proposal submitted - present new industrial applications and their impact on the sector and relevant markets.
- Describing the technology is the easy bit... Who are you? Describe the benefits of this partnership, the added value of each partner? Focus on the project methodology (objectives, means, results) and an appropriate and realistic cost breakdown. Analyse the risks and how you will mitigate these.
- Promote the key elements the evaluators are looking for and ask an objective party to read it. Proof-read it – this is the cheapest way of making it better.
- Don't allow yourself to be surprised by anything - Do your homework and speak to your National Project Coordinator (NPC).

# Factors for success

- Be available - Allow time for necessary preparation (partner search, project proposal, consortium agreement...)
- Build up a « win-win » cooperation - Show complementarities and added value of trans-national partnership during and after the project
- Show partnership's ability to meet its commitments - Demonstrate each party's management, scientific and technical skills as well as its available financial resources for the project
- Set clear, measurable and verifiable objectives - Define success indicators for technological performance as well as the commercial and financial targets to achieve
- Demonstrate clearly why the projects should be financed - Highlight the risks and the strategic character of the project in terms of expected commercial and financial impact, show value for money.

# EUREKA Clusters



## Industry led initiatives

Medium term  
Strategically significant  
International ecosystem of  
R&D&I actors




## Fostering European competitiveness

Develop generic technologies  
and standards  
Address economic and societal  
challenges



## Large number of participants

Major European industries  
Large SME participation  
(30–50% of partners)  
Research organisations and  
academia



# Cluster projects are...



Industry-driven  
supported by Public  
Authorities



Open to global  
cooperation



Covering the full  
value chain to create  
innovative solutions




Bottom-up



Helping SMEs to scale  
up in consortia with  
large industry



Market-oriented



# A typical Cluster project is...



**2-14**  
participants



**3-4**  
countries



average duration  
**30** months



average project cost  
**€1.5-15**  
million

# EUREKA Clusters



ICT and  
telecommunications



Smart electronic systems



Low carbon energy  
technologies



Software innovation



Advanced materials and  
manufacturing



Micro & nanoelectronics  
enabled systems and  
applications



Advanced manufacturing



Innovate  
UK

# Existing UK engagement in clusters

- UK currently participating in PENTA, Celtic next and SMART Clusters, though participants can self fund other Cluster participation.

Example Eligibility for recent PENTA call:


- To lead a project as a UK based organisation you must:
  - be a [business](#), of any size
  - involve at least one UK based [micro, small or medium sized enterprise](#) (SME)
- You can also collaborate with other UK based businesses of any size and UK based research organisations.
- Research organisations must be able to show how they will exploit the results of the project to grow the wider electronics, sensor and photonics sector in the UK. Research organisations cannot lead on an application.
- **Subcontractors**
- Your project can include subcontractors but they must not account for more than 20% of the total eligible project costs of the UK partners.



# EUREKA Globalstars



is a flexible, reliable, lean and fast instrument allowing global cooperation for EUREKA countries in a variable geometry.



# EUREKA Globalstars

In today's global economy, openness to international cooperation is becoming increasingly important. The **industry**, and especially the **SMEs**, in Europe and the associated member countries need to access new and **emerging markets**



EUREKA as a platform for global industrial R&D&I cooperation:

The innovation process and value chains in many technological areas and market areas extend beyond the boundaries of the current EUREKA network, indicating a future role for EUREKA as a platform for global industrial R&D&I cooperation.



The aim of the GlobalStars initiative is to facilitate international R&D&I cooperation between EUREKA countries, including associated countries, and non-EUREKA partner countries.

# EUREKA GLOBALSTARS calls eligibility criteria



Call collaboration between at least 2 EUREKA members and a GlobalStars partner country (or group of GlobalStars partner countries) outside the EUREKA Network.



Or alternatively: Call collaboration between 1 EUREKA member and 1 associated country and a GlobalStars partner country (or group of GlobalStars partner countries) outside the EUREKA Network.



On project level in the call, the minimum required number of participants should be 2 independent organisations, 1 organisation from a EUREKA member or associated country and 1 organisation from a GlobalStars partner country.

# UK engagement in EUREKA



Innovate  
UK



Ben Morris  
National  
Project  
Coordinator



Department for  
Business, Energy  
& Industrial Strategy

UK government  
representation by the  
UK Government  
department, Business  
Energy & Industrial  
Strategy (BEIS).




# Case studies

Case study

## Promethean: nanoparticle products go into full-scale production

Nottingham University spin-out builds on €10 million multi-partner EU project to enter global market in novel inks, paints and coatings.



**EUREKA**   
innovation across borders

## Videntifier project

### Helping international police forces investigating crime and terrorism

**Programme:** Eurostars and E!InnoVest

**Innovation:**

- Combines high-end computer vision techniques with blazingly fast database search
- Automatically compares huge amount of visual content in a fraction of the time it takes a human
- Identifies victims, perpetrators, and locations of crimes using large database
- Supports the process of scanning seized storage devices
- Uses visual fingerprints - a single point within an image that captures mathematical characteristics related to contrast and shape

**Partners:** Videntifier, Forensic Pathways, IRISA

**Countries involved:**    **Total R&D Investment:** €1,183,220

**Impact:**

- Credibility of EUREKA helped Videntifier to be appointed main tech provider to Interpol's International Child Exploitation database
- The project led to securing private investment and the company has subsequently grown in staff
- Technology deployed to globally to major law enforcement organisations including Korean National Police Agency, EUROPOL and the UK Home Office
- The company has expanded beyond the law enforcement domain to copyright protection and content monetisation
- Sold license to Facebook in the largest single company transaction to date in February



Innovate  
UK


Horizon Europe info is based on DRAFT  
Work Programme and is subject to change

# Thank you

To keep up to date with the latest Horizon Europe health funding news please sign up for our newsletter [here](#)

Presented by: Jo Frost [ncp-health@innovateuk.ukri.org](mailto:ncp-health@innovateuk.ukri.org)

[Other UK National Contact Points](#) / [National Contact Points for other countries](#)



**HORIZON EUROPE**

THE NEXT EU RESEARCH & INNOVATION  
PROGRAMME (2021 – 2027)